Cargando…
PARP Inhibitors for Cancer Therapy
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP-poly ADP ribose polymerase-in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discus...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Humana,
2015.
|
| Edición: | 1st ed. 2015. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-319-14151-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220117055142.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 150613s2015 sz | s |||| 0|eng d | ||
| 020 | |a 9783319141510 |9 978-3-319-14151-0 | ||
| 024 | 7 | |a 10.1007/978-3-319-14151-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a PARP Inhibitors for Cancer Therapy |h [electronic resource] / |c edited by Nicola J. Curtin, Ricky A. Sharma. |
| 250 | |a 1st ed. 2015. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Humana, |c 2015. | |
| 300 | |a XIX, 591 p. 108 illus., 85 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors. | |
| 520 | |a PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP-poly ADP ribose polymerase-in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors-PARPi-are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Medical microbiology. | |
| 650 | 0 | |a Medicine-Research. | |
| 650 | 0 | |a Biology-Research. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Medical Microbiology. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 700 | 1 | |a Curtin, Nicola J. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Sharma, Ricky A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783319141503 |
| 776 | 0 | 8 | |i Printed edition: |z 9783319141527 |
| 776 | 0 | 8 | |i Printed edition: |z 9783319344898 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-319-14151-0 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||